Evidence map›Paper›PMID 17879109›Full record

ArticleThe Journal of membrane biology2007

The ryanodine receptor pore blocker neomycin also inhibits channel activity via a previously undescribed high-affinity Ca(2+) binding site.

Derek R Laver, Tomoyo Hamada, James D Fessenden, Noriaki Ikemoto

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of membrane biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Vascular mechanotransduction.Physiological reviews · 2023
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Derek R LaverSchool of Biomedical Sciences, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia. Derek.Laver@newcastle.edu.au
Tomoyo Hamada
James D Fessenden
Noriaki Ikemoto
Boston Biomedical Research Institute · USHarvard University · USHunter Medical Research Institute · AU

Funding

Regulation of Normal and Diseased Cardiac Ca2+ ChannelsR01HL072841 · NHLBI · BOSTON BIOMEDICAL RESEARCH INSTITUTE · PI IKEMOTO, NORIAKI · 2003 to 2011
$3.5M
STRUCTURE/FUNCTION OF SARCOPLASMIC RETICULUMR01AR016922 · NIAMS · BOSTON BIOMEDICAL RESEARCH INSTITUTE · PI IKEMOTO, NORIAKI · 1986 to 2006
$3.5M
NHLBI NIH HHS HL072841NIAMS NIH HHS AR 16922
6 · The paper itself

Abstract

In this study, we present evidence for the mechanism of neomycin inhibition of skeletal ryanodine receptors (RyRs). In single-channel recordings, neomycin produced monophasic inhibition of RyR open probability and biphasic inhibition of [(3)H]ryanodine binding. The half-maximal inhibitory concentration (IC(50)) for channel blockade by neomycin was dependent on membrane potential and cytoplasmic [Ca(2+)], suggesting that neomycin acts both as a pore plug and as a competitive antagonist at a cytoplasmic Ca(2+) binding site that causes allosteric inhibition. This novel Ca(2+)/neomycin binding site had a neomycin affinity of 100 nM: and a Ca(2+) affinity of 35 nM,: which is 30-fold higher than that of the well-described cytoplasmic Ca(2+) activation site. Therefore, a new high-affinity class of Ca(2+) binding site(s) on the RyR exists that mediates neomycin inhibition. Neomycin plugging of the channel pore induced brief (1-2 ms) conductance substates at 30% of the fully open conductance, whereas allosteric inhibition caused complete channel closure with durations that depended on the neomycin concentration. We quantitatively account for these results using a dual inhibition model for neomycin that incorporates voltage-dependent pore plugging and Ca(2+)-dependent allosteric inhibition.

Indexed as

AnimalsBinding SitesCalciumDose-Response Relationship, DrugIon Channel GatingLipid BilayersMarkov ChainsMuscle, SkeletalNeomycinProtein BindingRabbitsRyanodineRyanodine Receptor Calcium Release ChannelCalciumLipid BilayersNeomycinRyanodineRyanodine Receptor Calcium Release Channel

Identifiers

PMID17879109
OpenAlexW2008715217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.